By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Modern medical technologies called molecular imaging devices make it possible to view and analyze biological processes at the molecular and cellular levels. In order to offer detailed information about the structure, function, and behavior of cells and tissues within living creatures, these gadgets integrate features of imaging technology and molecular biology.
The early identification, diagnosis, and treatment of many diseases, including as cancer, cardiovascular ailments, and neurological disorders, are greatly aided by molecular imaging. Targeting and seeing particular molecular markers or processes that are connected to particular diseases or biological occurrences is the main idea behind molecular imaging.
Proteins, enzymes, receptors, and other substances that are either naturally occurring in the body or that are delivered as a part of a diagnostic or therapeutic treatment can serve as these markers. Devices for molecular imaging employ a number of modalities, each of which has advantages and disadvantages.
In order to perform a molecular imaging procedure known as positron emission tomography (PET), radiotracers—radioactive molecules that are carefully made to bind to particular molecular targets—must be administered. The PET scanner detects the positrons that the radiotracers generate, which enables the creation of three-dimensional pictures that show the spatial distribution of the targeted molecules.
The molecular imaging technique known as single-photon emission computed tomography (SPECT) also makes use of radiotracers that generate gamma rays.
The foundation of SPECT imaging is the detection of gamma rays released by radiotracers during their natural decay. The body’s concentration and location of the targeted chemicals are revealed by SPECT, much like with PET. By using contrast agents that are specially made to interact with molecular targets, magnetic resonance imaging (MRI) can also be used for molecular imaging.
These contrast agents change the surrounding tissues’ magnetic properties, which improves the visibility of particular molecular processes or markers during an MRI scan. Additionally, molecular imaging frequently makes use of optical imaging methods including fluorescence imaging and bioluminescence imaging. These techniques make use of fluorescent or bioluminescent probes that produce light in response to certain wavelengths of light.
It is possible to see and detect the light that is emitted, which gives details on the location and dispersion of the molecules that are being studied. The use of molecular imaging technology has a big impact on many aspects of medicine. They are essential to the diagnosis, staging, and monitoring of cancer treatments in oncology.
By concentrating on particular cancer biomarkers, molecular imaging is able to detect the presence of tumors, rate their aggressivity, and gauge their therapeutic response. This data enables more individualized treatment regimens and better patient results. The identification and characterization of atherosclerotic plaques, which are the cause of numerous cardiovascular illnesses, including heart attacks and strokes, is made possible in cardiovascular medicine using molecular imaging tools.
These gadgets support risk assessment and the creation of focused therapies by viewing particular molecular markers linked to plaque growth and inflammation. Additionally, molecular imaging has uses in neuroscience that enable academics and medical professionals to investigate the molecular causes of neurological conditions and monitor the outcomes of therapeutic therapies.
Molecular imaging tools aid in our understanding of illnesses including Alzheimer’s disease, Parkinson’s disease, and epilepsy by viewing specific molecules involved in brain function and disease processes. To sum up, molecular imaging tools are complex instruments that integrate imaging technology and molecular biology to observe and examine biological processes at the cellular and molecular levels.
These tools have transformed the fields of diagnostics, therapeutics, and biomedical research by permitting individualized and focused treatment strategies and by illuminating important disease mechanisms. Molecular imaging is anticipated to keep playing a crucial part in enhancing patient care and expanding medical knowledge as a result of current breakthroughs and developments.
The Global Molecular Imaging Device Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
The first-of-its-kind Omni Legend PET-CT system from GE Healthcare is designed to improve diagnostics, increase efficiency, and support precision medicine. An improved digital detector with the capacity to produce high-resolution images and remarkable image quality with increased clinical efficacy is the foundation of the ground-breaking, unique technology known as Omni Legend.
In addition to accommodating patients in additional care settings, the Omni PET/CT platform has a scalable design that makes it simple to enable future-ready features and multi-dimensional scalability. Precision DL, a new deep learning image processing program, and the flexibility to scan with new, emerging tracers in addition to FDG may be found in the design of the new system.
These tracers can enable other processes, such as the diagnostics component of theranostics imaging. The first system on its brand-new, entirely digital PET/CT platform, Omni Legend is proudly unveiled by GE Healthcare at the European Association of Nuclear Medicine (EANM) Annual Meeting.
This state-of-the-art device uses an entirely new class of digital BGO (dBGO) detector material with a small crystal size that offers more than twice the sensitivity of earlier digital scanners, enabling quicker total scan times and outstanding minor lesion detectability. It is intended to increase diagnostic power, improve operational efficiency, and improve the patient experience, thus enabling better patient outcomes.
Additionally, the system’s theranostics capabilities, capacity to image short-lived tracers, dynamic protocols, and other features give clinicians access to more clinical data than ever before for a wider range of oncology, cardiology, and neurology operation types. Health plan leaders see their top two issues as achieving operational efficiency and controlling costs as the pace of change in the healthcare industry quickens.
This is in line with remarks made by international molecular imaging departments, which identify operational effectiveness as the main obstacle to increasing the number of PET/CT procedures.
Its new Precision DL solution for deep learning image processing in PET/CT, as well as its AI-based Auto Positioning Camera, are just two examples of how GE Healthcare’s Omni Legend helps healthcare systems get past current obstacles. Omni Legend is GE Healthcare’s response to these growing challenges.
